
@Article{or.2026.083013,
AUTHOR = {Laura Ordas, Malick Bio Idrissou, Dan Cappabianca, Ohyun Kwon, Bryan Bednarz, Reinier Hernandez, Quaovi H. Sodji},
TITLE = {Low Dose Radiation by Lutetium-177 Abrogates NK-92 Cell Proliferation without Compromising Cytotoxicity against Prostate Cancer Cells},
JOURNAL = {Oncology Research},
VOLUME = {},
YEAR = {},
NUMBER = {},
PAGES = {{pages}},
URL = {http://www.techscience.com/or/online/detail/28231},
ISSN = {1555-3906},
ABSTRACT = {Objectives: Adoptive natural killer (NK) cell therapy is a promising “off-the-shelf” approach for advanced solid malignancies. NK-92 cells can be expanded at scale and have broad antitumor activity but require irradiation to prevent <i>in vivo</i> proliferation. Standard 10 Gy γ-irradiation halts NK-92 cell proliferation but rapidly reduces cytotoxicity, thereby limiting therapeutic benefit. This study evaluated whether low-dose β-particle irradiation delivered by Lutetium-177 (<sup>177</sup>Lu) suppresses NK-92 cell proliferation while preserving cytotoxicity and explored its combination with radiopharmaceutical therapy (RPT). Methods: NK-92 cells were exposed to low doses of radiation delivered by <sup>177</sup>Lu and compared with equivalent doses administered by external beam radiation therapy (EBRT). Proliferation and cytotoxicity against prostate cancer cells were assessed after irradiation. We also evaluated whether <sup>177</sup>Lu pre-irradiation of tumor cells influenced NK-92-mediated cytotoxicity and expression of NK-regulatory ligands including Fas, MICA/B and HLA-E. Results: Low absorbed doses of <sup>177</sup>Lu suppressed NK-92 cell proliferation while preserving cytotoxicity, unlike equivalent EBRT doses. NK-92 cells maintained antitumor activity in the presence of <sup>177</sup>Lu. Pre-irradiated tumor cells were more susceptible to NK-92 cell killing, but this effect was not further enhanced by disruption of the NKG2A/HLA-E axis. <sup>177</sup>Lu increased tumor cell expression of Fas and MICA/B, suggesting a potential mechanism for enhanced cytotoxicity.},
DOI = {10.32604/or.2026.083013}
}



